Welcome to our Clinical Studies section
Development of new drugs
UCB researchers seek to understand, prevent and treat diseases.
Clinical studies involving healthy volunteers and patients play a vital role in the development of new drugs.
Patients are enrolled in clinical studies that are consistent with the principles that have their origin in the Declaration of Helsinki and its amendments as well as the laws, regulations and provisions of those countries where humans are enrolled.
Find out more about a selection of studies

A Randomized, Dose-Finding and Confirmatory, Double-Blind, Placebo-Controlled, Parallel-Group Multicenter Study With a 2 Stage Adaptive Design and Randomized Withdrawal to Evaluate the Efficacy, Safety, and Tolerability of Brivaracetam as Monotherapy in Patients 2 to 25 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy

A Patient- and Investigator-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Bepranemab (UCB0107) in Study Participants With Prodromal to Mild Alzheimer’s Disease (AD), Followed by an Open-Label Extension Period

A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 3, Pivotal Study With an Open-Label Extension Period to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-Associated Disease (MOG-AD)

A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Rozanolixizumab in Adult Study Participants With Leucine-Rich Glioma Inactivated 1 Autoimmune Encephalitis

A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Outpatient, Parallel-Group Study to Assess the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures

An Open-Label, Multicenter, Outpatient Extension Study to Evaluate the Safety and Tolerability of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures

A Double-Blind, Placebo-Controlled, Randomized, 18-Month Phase 2a Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Oral UCB0599 in Study Participants With Early Parkinson’s Disease

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus

A Postmarketing, Multicenter, Longitudinal, Prospective, Pharmacokinetic, Phase 1B Study in Pregnant Women With Chronic Inflammatory Diseases Treated With Cimzia (Certolizumab Pegol)

Multicenter, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled (12-17 Years) Including a Single Open-Label Arm (6-11 Years) Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Certolizumab Pegol (CZP) in Pediatric Study Participants With Moderate to Severe Chronic Plaque Psoriasis (PSO)

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled StudyA Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Bimekizumab in Subjects With Active Nonradiographic Axial Spondyloarthritis.
Discover more about our clinical studies

Interested in enrolling in our study?
Just contact us
Austria
UCBCares.AT@ucb.com
+43 (0) 1 291 80 08
0800-296176 (freephone)
Belgium
UCBCares.BE@ucb.com
+32 2 559 92 00
0800 38 008 (freephone)
www.ucbcares.be
Bulgaria
UCBCares.BG@ucb.com
+359 2 962 9933
www.ucbcares.bg
Czech Republic
UCBCares.CZ@ucb.com
+420 221 773 442
800 144 395 (freephone)
www.ucbcares.cz
Denmark
UCBCares.DK@ucb.com
+45 32462480
80 253827 (freephone)
www.ucbcares.dk
Finland
UCBCares.FI@ucb.com
+358 942733300
0800 9 13353 (freephone)
www.ucbcares.fi
France
UCBCares.FR@ucb.com
+33 1 47 29 45 55
0 805 222 949 (freephone)
www.ucbcares.fr
Germany
UCBCares.DE@ucb.com
+49 2173 48 48 48
www.ucbcares.de
Greece
UCBCares.GR@ucb.com
+30 21 0997 4200
0080 012 9910 (freephone)
www.ucbcares.gr
Hungary
UCBCares.HU@ucb.com
+36 1 472 5060
06 80 021 486 (freephone)
www.ucbcares.hu
Ireland
UCBCares.IE@ucb.com
+353 1 463 2371
1800 93 00 75 (freephone)
www.ucbcares.co.uk
Italy
UCBCares.IT@ucb.com
+39 02 3007 9300
8009-86932 (freephone)
www.ucbcares.it
Japan
Luxemburg
UCBCares.LU@ucb.com
+32 2 559 92 12
8002 3204 (freephone)
Norway
UCBCares.NO@ucb.com
+45 32462482
800-10101 (freephone)
www.ucbcares.no
Poland
UCBCares.PL@ucb.com
+48 22 596 97 97
00 800 121 68 25 (freephone)
www.ucbcares.pl
Portugal
UCBCares.PT@ucb.com
+351 213 025 300
800-8-56033 (freephone)
Romania
+4021 300 19 07
Slovakia
UCBCares.SK@ucb.com
+421 2 592 020 23
0800 002 566 (freephone)
www.ucbcares.sk
Spain
UCBCares.ES@ucb.com
+34 915 70 06 49
8000-99684 (freephone)
www.ucbcares.es
Sweden
UCBCares.SE@ucb.com
+45 32462481
0200 898 671 (freephone)
www.ucbcares.se
Switzerland
+41 58 822 3180
The Netherlands
UCBCares.NL@ucb.com
+31 76 573 1130
0800 3434335 (freephone)
www.ucbcares.nl
UK
UCBCares.UK@ucb.com
+44 1753 777 100
0800 279 3177 (freephone)
www.ucbcares.co.uk
USA
UCBCares@ucb.com
+1-844-599-2273
www.ucb-usa.com/Patients/Patients

People don't see my disease and how it threatents my independence,
and those same people don't realise that they, too, could be at risk.
Lut, living with osteoporosis
Disease resources
Choose a Country
- Global Site – English
- Australia – English
- België – Engels
- Belgique – Anglais
- Brasil – Português
- България – Български
- Canada – English
- Canada – Français
- 中国 – 中文
- Česká Republika – Angličtina
- Danmark – Engelsk
- Deutschland – Deutsch
- France – Français
- España – Español
- Ελλάδα – Ελληνικά
- India – English
- Ireland – English
- Italia – Inglese
- 日本 – 日本語
- 한국 – 한국어
- Luxembourg – Anglais
- Luxemburg – Engels
- Magyarország – Angol
- México & Latinoamérica – Español
- Nederland – Engels
- New Zeeland – English
- Norge – Engelsk
- Österreich – Deutsch
- Polska – Polski
- Portugal – Inglês
- România – Engleză
- Россия – Русский
- Slovensko – Anglický
- Suomi – Englanti
- Sverige – Engelska
- Schweiz – Deutsch
- Türkiye – Türkçe
- Україна – Англійська
- United Kingdom – English
- U.S.A. – English
Our Company
Disease Areas
Our Science
Our Products
Newsroom
Patients
Investors
Clinical Studies
Advantage Hers
- Advantage Hers English
- Advantage Hers German
- Advantage Hers French
- Advantage Hers Spanish
- Advantage Hers Italian
- Advantage Hers Danish
- Advantage Hers Dutch
- Advantage Hers Polish
- Advantage Hers Greek
- Advantage Hers Finnish
- Advantage Hers Norwegian
- Advantage Hers Romanian
- Advantage Hers Bulgarian
- Advantage Hers Czech
- Advantage Hers Slovak
- Advantage Hers Australia
- Advantage Hers Canada